Zymeworks (ZYME)
(Delayed Data from NSDQ)
$8.33 USD
+0.07 (0.85%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $8.31 -0.02 (-0.24%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Income Statements
Fiscal Year end for Zymeworks Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 76 | 412 | 27 | 39 | 30 |
Cost Of Goods | 144 | 209 | 200 | 169 | 116 |
Gross Profit | -68 | 204 | -173 | -130 | -86 |
Selling & Adminstrative & Depr. & Amort Expenses | 70 | 73 | 43 | 58 | 65 |
Income After Depreciation & Amortization | -138 | 131 | -216 | -187 | -151 |
Non-Operating Income | 19 | 5 | 3 | 7 | 6 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -119 | 135 | -212 | -180 | -146 |
Income Taxes | -1 | 11 | -1 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -119 | 124 | -212 | -181 | -145 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -119 | 124 | -212 | -181 | -145 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -128 | 143 | -206 | -177 | -144 |
Depreciation & Amortization (Cash Flow) | 10 | 12 | 10 | 10 | 7 |
Income After Depreciation & Amortization | -138 | 131 | -216 | -187 | -151 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 68.86 | 65.25 | 52.13 | 50.38 | 38.02 |
Diluted EPS Before Non-Recurring Items | -1.72 | 1.90 | -4.61 | -3.58 | -3.83 |
Diluted Net EPS (GAAP) | -1.72 | 1.90 | -4.61 | -3.58 | -3.83 |
Fiscal Year end for Zymeworks Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 16.93 | 16.51 | 7.00 | 35.58 |
Cost Of Goods | NA | 25.52 | 32.78 | 39.41 | 45.91 |
Gross Profit | NA | -8.60 | -16.27 | -32.41 | -10.33 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 14.82 | 16.97 | 21.71 | 16.95 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -23.42 | -33.24 | -54.12 | -27.28 |
Non-Operating Income | NA | 4.22 | 5.66 | 4.62 | 4.32 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -19.20 | -27.58 | -49.50 | -22.96 |
Income Taxes | NA | -4.72 | 1.11 | 1.65 | 1.39 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -14.48 | -28.69 | -51.15 | -24.35 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -14.48 | -28.69 | -51.15 | -24.35 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 70.83 | 70.58 | 67.29 | 66.74 |
Diluted EPS Before Non-Recurring Items | NA | -0.20 | -0.41 | -0.76 | -0.37 |
Diluted Net EPS (GAAP) | NA | -0.18 | -0.41 | -0.76 | -0.37 |